Genfit (GNFT) Competitors

Genfit (NASDAQ:GNFT) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.

Which has better earnings and valuation, GNFT or LENZ?

Genfit has higher revenue and earnings than LENZ Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genfit	$76.06M	2.26	-$31.27M	N/A	N/A
LENZ Therapeutics	N/A	N/A	-$124.65M	N/A	N/A

Is GNFT or LENZ more profitable?

Genfit's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genfit	N/A	N/A	N/A
LENZ Therapeutics	N/A	-58.48%	-55.50%

Which has more risk & volatility, GNFT or LENZ?

Genfit has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in GNFT or LENZ?

2.2% of Genfit shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 4.2% of Genfit shares are owned by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts rate GNFT or LENZ?

Genfit presently has a consensus price target of $13.00, suggesting a potential upside of 277.91%. LENZ Therapeutics has a consensus price target of $35.40, suggesting a potential upside of 52.59%. Given Genfit's higher possible upside, analysts plainly believe Genfit is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genfit	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
LENZ Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Does the MarketBeat Community favor GNFT or LENZ?

Genfit received 58 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 69.39% of users gave Genfit an outperform vote.

Company	Underperform	Outperform
Genfit	Outperform Votes 68 69.39%	Underperform Votes 30 30.61%
LENZ Therapeutics	Outperform Votes 10 100.00%	Underperform Votes No Votes

Does the media favor GNFT or LENZ?

In the previous week, LENZ Therapeutics had 2 more articles in the media than Genfit. MarketBeat recorded 6 mentions for LENZ Therapeutics and 4 mentions for Genfit. LENZ Therapeutics' average media sentiment score of 1.10 beat Genfit's score of 0.92 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genfit	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LENZ Therapeutics beats Genfit on 8 of the 15 factors compared between the two stocks.